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ABSTRACT 
Hyalinizing trabecular adenoma/tumor (HTT) is a rare and poorly characterized follicular-derived 
thyroid neoplasm recently shown to harbor recurrent PAX8-GLIS1 or PAX8-GLIS3 gene fusions. 
Here we sought to define the repertoire of genetic alterations of HTTs, and whether PAX8-GLIS3 
fusions are pathognomonic for HTTs. A discovery series of 8 HTTs was subjected to RNA-
sequencing (n=8), whole-exome sequencing (n=3) or targeted massively parallel sequencing 
(n=5). No recurrent somatic mutations or copy number alterations were identified in HTT, 
whereas RNA-sequencing revealed the presence of a recurrent genetic rearrangement involving 
PAX8 (2q14.1) and GLIS3 (9p24.2) genes in all cases. In this in-frame fusion gene, which 
comprised exons 1-2 of PAX8 and exons 3-11 of GLIS3, GLIS3 is likely placed under the 
regulation of PAX8. Reverse transcription (RT)-PCR and/or fluorescence in situ (FISH) analyses 
of a validation series of 26 HTTs revealed that the PAX8-GLIS3 gene fusion was present in all 
HTTs (100%). No GLIS1 rearrangements were identified. Conversely, no PAX8-GLIS3 gene 
fusions were detected in a cohort of 237 control thyroid neoplasms, including 15 trabecular 
thyroid lesions highly resembling HTT from a morphological standpoint, as well as 
trabecular/solid follicular adenomas, solid/trabecular variants of papillary carcinoma, and Hurthle 
cell adenomas or carcinomas. Our data provide evidence to suggest that the PAX8-GLIS3 fusion 
is pathognomonic for HTTs, and that the presence of the PAX8-GLIS3 fusion in thyroid 
neoplasms may be used as an ancillary marker for the diagnosis of HTT, thereby avoiding 
overtreatment in case of misdiagnoses with apparently similar malignant tumors. 
 
KEY WORDS: hyalinizing trabecular tumor, thyroid, PAX8, GLIS3, gene fusion, differential 
diagnosis. 
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INTRODUCTION 
Hyalinizing trabecular adenoma/tumor (HTT) is a rare follicular-derived, thyroglobulin producing, 
thyroid neoplasm composed of large trabeculae of elongated or polygonal eosinophilic cells 
admixed with intratrabecular hyaline material of the basal membrane type. HTT shares many 
nuclear features of those of papillary thyroid carcinoma (PTC), namely nuclear clearing, grooves, 
pseudoinclusions and irregular borders (1). This tumor was described as a benign follicular tumor 
(a single malignant case is on record among 118 benign HTTs reviewed some years ago) (2, 3) 
and was variably named, as either adenoma or tumor or neoplasm of uncertain malignant 
potential. No etiological or risk factors are known for HTT and a real understanding of its nature 
is missing (2). An association with PTC is reported in up to 5% of cases and HTT itself has been 
related to PTC based on shared morphological features and RET gene alterations in a fraction of 
cases (4, 5). Besides RET-PTC rearrangements, no other PTC-related genetic abnormalities, 
such as BRAF mutations (6) or microRNA expression (7, 8), have been described in association 
with HTT. Similarly, no follicular tumor–related alterations were found, including RAS gene 
mutations or PAX8-PPARgamma rearrangements, the latter originally claimed to be specific of 
follicular carcinomas (9). 
Very recently, Nikiforova and co-workers (10) have reported on the presence of gene fusions 
involving PAX8 and GLIS genes as pathognomonic genomic features underlying HTT. These 
fusions, in particular the PAX8–GLIS3 rearrangement, were identified in 100% of tumors with 
cardinal unequivocal morphological and immunophenotypical features of HTT. By performing a 
thorough genomic characterization of this entity, the same authors were also able to show that 
HTT typically shows a quiet genome with a low number of somatic mutations and no significant 
DNA copy number alterations (10). 
In this study, we provide a thorough independent validation of the presence of the PAX8–GLIS3 
fusion in a large multi-institutional series of 34 HTTs, as opposed to its absence in 237 control 
thyroid neoplasms that also included 15 trabecular tumors of follicular derivation highly 
resembling HTT from a morphological standpoint, thus posing a potential diagnostic 
interpretational issue in both histopathologic and fine needle aspiration cytology diagnostic 
practice. 
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MATERIAL AND METHODS 
Cases 
After obtaining approval by the IRBs and local research ethics committees from the authors’ 
institutions, the pathology files of the authors’ institutions (Città della Salute Hospital and 
Mauriziano Hospital in Torino, Italy; San Luigi Hospital in Orbassano-Torino, Italy; Service of 
Clinical Pathology, Lausanne University Hospital, Switzerland; IRCCS in Reggio Emilia, Italy; 
Cleveland Clinic, Ohio, USA; Ottawa Hospital, Canada) were searched for a diagnosis of either 
“hyalinizing trabecular tumor” or “hyalinizing trabecular adenoma” of the thyroid. Samples were 
anonymized prior to the analyses. Representative hematoxylin & eosin (H&E) and Ki67/MIB1 
stained slides of 38 HTTs were centrally reviewed by two pathologists with a expertise in thyroid 
neoplasms (MV and MP). The diagnosis of HTT was based on the strict diagnostic criteria 
reported in the WHO classification of endocrine tumors of the thyroid (1), as well as in previous 
publications (11, 12). Upon pathological review, 34 cases were unanimously diagnosed as HTT; 
four cases were excluded and reclassified as follicular adenomas of the trabecular or Hurthle cell 
type (three tumors: # 13T, 15T, 23T) and as Hurthle cell carcinoma based on signs of vascular 
invasion in the remaining case (# 24T) (Figure 1). 
Of the 34 HTTs included in this study, four (HTT02, HTT06, HTT12, HTT33) also contained a 
small, classical PTC in the same thyroid lobe, but topographically independent from the HTT 
nodule. In addition, a separate series of 237 neoplasms that represented a comprehensive 
landscape of thyroid lesions were used as controls, and comprised 119 PTCs, 24 follicular 
carcinomas, 13 poorly differentiated carcinomas, 25 anaplastic carcinomas, 15 medullary 
carcinomas, 18 Hurthle cell tumors, and 23 follicular adenomas (Figure 1). Within this series, 15 
tumors showed morphological features highly reminiscent of HTT, i.e. prominent solid/trabecular 
growth pattern and more or less extensive hyalinization. These were appropriately classified in 
different categories (i.e. follicular adenomas of trabecular/embryonal variant, solid/trabecular 
variant of papillary carcinomas, Hurthle cell adenomas, Hurthle cell carcinoma). 
First, eight HTTs were subjected as a discovery series to RNA- and DNA-sequencing (Figure 1). 
Subsequently, a validation series of 26 HTTs were subjected to reverse transcription (RT)-PCR 
and fluorescence in situ (FISH) analyses (Figure 1). 
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Microdissection and nucleic acid extraction 
Eight-micron-thick sections were cut from formalin fixed paraffin embedded (FFPE) blocks of the 
tumor and normal thyroid tissue, stained with nuclear fast red and microdissected under a 
stereomicroscope as previously described (13) to ensure >80% of tumor cells content and that 
the normal tissue was devoid of neoplastic cells. RNA and genomic DNA were extracted and 
quantified as previously described (14). 
 
Immunohistochemistry 
Four-micron-thick sections were cut from the representative FFPE block of each HTT and 
processed for Ki67 immunohistochemistry with an automatic immunostainer (Ventana 
BenchMark AutoStainer, Ventana Medical Systems, Tucson, USA), with the exception of the 
primary antibody incubation step, which was manually performed at room temperature for 30 
minutes using the Ki67 clone MIB1 (Dako/Agilent, Glostrup, Denmark) diluted 1/50, after antigen 
retrieval with the commercial Ventana CC1 solution for 36 minutes. The evaluation of Ki67 relied 
on a qualitative assessment of the staining pattern of staining (membranous versus nuclear).  
 
Whole-exome and targeted massively parallel sequencing 
Microdissected tumor and normal DNA samples from eight HTTs (discovery set) were subjected 
to whole-exome sequencing (WES, n=3) (15) and to Memorial Sloan Kettering-Integrated 
Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) sequencing (n=5; Figure 1), 
which targets all exons and selected introns of 410 cancer genes, as previously described (16, 
17) (Supplementary Table S1). Three additional cases from the validation set were also 
subjected to MSK-IMPACT (Figure 1). 
Analysis of sequencing data was performed as previously described (15, 17). In brief, somatic 
single-nucleotide variants (SNVs) were detected using MuTect (v1.0) (18), and small insertion 
and deletions (indels) by Strelka (v2.0.15) (19), VarScan2 (v2.3.7) (20), Lancet (v1.0.0) (21) and 
Scalpel (v0.5.3) (22). SNVs and indels for which the tumor mutant allele fraction (MAF) was <5 
times that of the matched normal MAF were excluded. SNVs and indels found at >1% global 
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minor allele frequency in ExAC (23), as well as common SNPs reported in dbSNP (build 150) 
were also excluded. Copy number alterations (CNAs) and loss of heterozygosity (LOH) were 
defined using FACETS (24). ABSOLUTE (v1.0.6) (25) was employed to determine the cancer 
cell fraction (CCF) of each mutation, as previously described (15, 17). A mutation was classified 
as clonal if its probability of being clonal was >50% or if the lower bound of the 95% confidence 
interval of its CCF was >90%, as previously described (15, 17). Mutations affecting hotspot 
codons were annotated according to Chang et al (26). 
 
RNA-sequencing and fusion gene identification 
RNA-sequencing was performed on eight HTTs (Figure 1, Supplementary Table S1) using 
validated protocols (15) employed at MSKCC’s Integrated Genomics Operation (IGO). In brief, 
paired-end RNA-sequencing was performed with 2 × 50 bp cycles on an Illumina HiSeq2000. 
Read pairs supporting fusion transcripts were identified using INTEGRATE (27), deFuse (28) and 
FusionCatcher (29), as previously described (15, 30). To account for alignment artifacts and 
normal transcriptional variants, we excluded fusion gene and read-through candidates that were 
also identified in a set of 297 normal samples from TCGA (31). The remaining in-frame candidate 
fusion genes were annotated using OncoFuse (32) to define their likelihood of constituting 
potential driver fusion genes. The presence of the in-frame candidate fusion genes identified was 
also assessed across 33 cancer types in the tumor fusion gene data portal (33) which comprises 
a list of 20,231 fusion genes. 
 
PAX8-GLIS3 FISH analysis 
PAX8-GLIS3 fusion gene assessment by FISH was performed using validated protocols at 
MSKCC’s Molecular Cytogenetics Core, as previously described (34). Three-color PAX8-GLIS3 
probe were employed, consisting of bacterial artificial chromosomes (BACs) mapping to 5’PAX8 
(green), 3’PAX8 (red) and 3’GLIS3 (orange). At least ten images per tumor region were captured 
and at least 50 non-overlapping interphase nuclei with well-delineated contours were analyzed 
for the presence of the PAX8-GLIS3 fusion. HTTs were considered positive for the PAX8-GLIS3 
fusion gene if >15% of the cells displayed at least one 5’PAX8-3’GLIS3 fusion signal. 
  8
 
Reverse Transcription-PCR (RT-PCR) 
Total RNA was reverse-transcribed using SuperScript Vilo Master Mix (Life Technologies; 
Thermo Fisher Scientific), according to the manufacturer’s instructions. PCR amplification of 
10ng of cDNA was performed using specific primer sets designed based on the known fusion 
genes and breakpoints (Supplementary Table S2). PCR fragments were purified (ExoSAP-IT, 
Affymetrix) and sequenced on an ABI 3730 capillary sequencer using the ABI BigDye Terminator 
chemistry (v3.1, Life Technologies) according to the manufacturer’s protocol. Sequences of the 
forward and reverse strands were analyzed using MacVector software (MacVector, Inc., Cary, 
NC, USA). All analyses were performed in duplicate. 
 
RESULTS 
Histologic features 
All 34 HTTs included in this study displayed the cardinal morphological features of HTT: a growth 
pattern made of thick trabeculae; elongated or -more rarely- polygonal cells arranged with a 
perpendicular orientation compared to the trabecular axis; eosinophilic cytoplasm and clear 
nuclei with irregular borders, grooves and pseudoinclusions; and finally presence of more or less 
abundant intratrabecular hyaline material often embedding single or groups of tumor cells (Figure 
2). In addition, all HTTs displayed immunoreactivity at the cell membrane for the MIB1 
monoclonal antibody to Ki67 (Figure 2). 
The 237 control cases, whose histology is detailed in Supplementary Table S3, had the 
expected morphology for each single tumor entity, with the exception of 15 selected cases that 
had a prominent solid and/or trabecular growth pattern and more or less extensive signs of 
hyalinization that resembled HTT, but were eventually classified as variants of follicular adenoma 
(trabecular/embryonal variant, n=8), Hurthle cell adenoma (solid/trabecular patterns, n=2), 
papillary carcinoma (solid/trabecular variant, n=3), Hurthle cell carcinoma (solid/trabecular 
patterns, n=1) and poorly differentiated carcinoma (trabecular variant, n=1) (Figure 1). In all such 
cases, an HTT was originally suspected or diagnosed, based on the trabecular growth pattern 
and the presence of stromal hyaline material. The trabeculae were generally thin and merged, 
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however, with compact solid nests made of cells haphazardly oriented along the axis of the cords 
(rather than perpendicularly) and with a deeply eosinophilic and granular cytoplasm, as 
commonly seen in Hurthle cells neoplasms. In addition and more importantly, the variable degree 
of hyaline material was in any case restricted to the space between the trabeculae and was not 
distributed inside them (with the tight contact to neoplastic cells typically observed in HTT). 
Finally, in all other thyroid neoplasms included the diagnosis of HTT was not supported due to 
the lack of the peculiar cell membrane reactivity pattern for Ki67/MIB1 (Figure 3). 
 
Mutational landscape and copy number alterations in HTT 
To assess the somatic genetic alterations, three and eight cases were subjected to WES 
(median depth of coverage of tumor 139x (range 137x-164x), and normal 151x (range 131x-
161x) samples) and targeted MSK-IMPACT sequencing (median depth of coverage of tumor 
311x (range 18x-499x), and normal 174x (range 41x-530x) samples), respectively 
(Supplementary Table S4). 
HTTs displayed a low tumor burden, with a median of 16 (range 10-22) somatic mutations 
defined by WES, of which 11 (range 9-19) were non-synonymous, while the MSK-IMPACT assay 
detected a median of 1 (range 1-2) somatic mutations of which 1 (range 1-2) were non-
synonymous. No recurrent somatic mutations were identified in the HTTs analyzed. The majority 
of mutations were non-pathogenic missense mutations not affecting hotspot residues, and four 
HTTs subjected to MSK-IMPACT sequencing did not harbor any mutations affecting the 410 
cancer-related genes tested (Supplementary Figure S1). The potentially pathogenic non-
synonymous mutations identified included a subclonal FIP1L1 (p.L26R) missense mutation and a 
clonal ITK (p.R581W) missense mutation in HTT10 and HTT11, respectively. Analysis from 
MSK-IMPACT demonstrated a subclonal SPEN (p.P1892Qfs*6) frameshift mutation and a clonal 
KDM5A (p.R719H) missense mutation in HTT01, and a subclonal TP63 (p.X549) splice site 
mutation in HTT08 (Supplementary Figure S1, Supplementary Table S5). 
Genome copy number analysis revealed a diploid/near-diploid genome in the 11 HTTs analyzed 
in this study (Supplementary Figure S2). No homozygous deletions or high-level amplifications 
were found in the HTTs analyzed. 
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PAX8-GLIS3 fusion detection and validation in HTT 
Based on the initial findings of a quiet genome and lack of recurrent pathogenic somatic 
mutations, the eight HTTs of our discovery series were subjected to global RNA-sequencing 
analysis, which detected the presence of a recurrent, in-frame PAX8-GLIS3 fusion gene (8/8, 
100%), resulting in a chimeric transcript composed of exons 1-2 of PAX8 and exons 3-11 of 
GLIS3 (Figure 4A, Supplementary Table S2). The fusion of exons 1-2 of PAX8 to the 3’-end of 
GLIS3 results in the increased expression of exons 3-11 of GLIS3, as assessed using the RPKM 
counts (Figure 4B). In the eight HTTs and in validation series of 26 HTTs, the PAX8-GLIS3 
fusion gene was confirmed/ present by FISH (n=12) and/or RT-PCR (n=33) in all HTTs (100%; 
Figure 4C-D, Supplementary Table S3). Four HTTs had a concurrent PTCs, and whilst the 
PAX8-GLIS3 fusion gene was present in the HTT, it was absent in the PTCs of these cases 
(Figure 5). 
 
Lack of PAX8-GLIS3 fusions in thyroid neoplasms 
To determine whether PAX8-GLIS3 rearrangements would constitute a pathognomonic genetic 
alteration in the HTTs, FISH and RT-PCR were performed in the series of 237 control cases, 
which included the whole spectrum of conventional thyroid neoplasms and also encompassed a 
subgroup of 15 tumors of follicular derivation characterized by a prominent trabecular growth and 
hyalinization that was reminiscent of HTT on sole morphological ground. None of these controls 
and potential differential diagnoses of HTT harbored the PAX8-GLIS3 rearrangement (Figure 4E, 
Supplementary Table S3). In addition, none of the 9,950 tumors from 33 cancer types from The 
Cancer Genome Atlas (33) were found to harbor the specific PAX8-GLIS3 fusion (Figure 4F). 
These data provide evidence to suggest that the PAX8-GLIS3 fusion is pathognomonic for HTTs. 
 
DISCUSSION 
Here we present a validation of the recently reported PAX8-GLIS3 rearrangement (10) 
as a hallmark genomic feature of the rare hyalinizing trabecular tumor (HTT) of the thyroid. In 
agreement with Nikiforova et al. findings (10), all of the 34 histologically proven HTTs of the 
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present study harbored the PAX8-GLIS3 fusion. This gene rearrangement has been consistently 
demonstrated by different techniques, using specifically designed probes, which confirmed the 
occurrence of such rearrangement. In parallel, this fusion gene was not present in control thyroid 
tumors of various histologies, including an interesting series of trabecular tumors of follicular 
derivation that was specifically selected from our files for the purpose of testing the power of this 
novel fusion, as a potential differential diagnostic marker. 
The origin of HTT is unknown. No risk factors have so far been reported and the 
claimed relationship with PTC had been challenged by the absence of BRAF mutations (6), and 
now definitely excluded by the specific PAX8-GLIS3 rearrangement (or PAX8-GLIS1, as reported 
by Nikiforova et al. (10)), that never occurred in the 300 papillary cancers so far analyzed in 
published (10) and in the present series, with one exception in the Nikiforova’s series (10) and in 
the TGCA series of 484 PTCs (35). The case regarded a trabecular tumor focally reminiscent of 
HTT that was eventually diagnosed as a PTC and probably represents the same case used in 
the two different publications (10). With regard to follicular adenoma and carcinoma, the 
similarities with HTT are even more scant on both morphological and genetic grounds. Besides 
RAS gene mutations, follicular adenomas and carcinomas were found to harbor a rearrangement 
of PAX8-PPARgamma genes that was originally reported to be restricted to malignant conditions, 
only (9), but subsequently identified also in a fraction of follicular adenomas, although never in 
HTT. Interestingly, the novel HTT-specific fusion is also correlated to the PAX8 gene, although 
the fusion occurred with another locus, mapping to chromosome 9p24.2 to produce the PAX8-
GLIS3 rearrangement, or to chromosome 1 in the case of the rarer GLIS1 type fusion (10). 
Although the newly discovered genetic alteration may not bear any impact in the 
therapeutic strategy of the patients, since surgery is generally sufficient to cure the tumor, the 
novel fusion product represents a relevant diagnostic tool of this rare tumor in surgical samples 
and, in particular, in preoperative cytology specimens, in which the diagnosis of HTT is reached 
in no more than 8% of cases (36). In fact, the differential diagnosis from solid/trabecular variants 
of papillary carcinoma may occasionally pose problems due to the overlapping nuclear features 
of the two tumors, while genetically the two entities seem unrelated with a predominance of 
BRAF and RAS gene mutations in papillary cancer, but not in HTT (6). In addition, even follicular 
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neoplasms may resemble HTT when the growth pattern is predominantly trabecular or solid, as 
seen in embryonal/fetal type follicular adenomas or in poorly differentiated carcinomas. The 
commonly shared thyroglobulin production is of no help in this setting of differential diagnosis, 
and the only useful HTT marker is the peculiar membrane pattern (artefactually) produced by 
Ki67 immunostaining, provided specific technical conditions are met (i.e. use of MIB1 monoclonal 
and room temperature incubation), in order to obtain the expected cell membrane reactivity (37). 
Although diagnostic criteria for both HTT and its mimickers are apparently clear-cut, it is 
the experience of some of us that in the daily consultation practice, a certain degree of confusion 
exists among the different entities. The major source of controversies is the presence of more or 
less hyalinized stroma in an otherwise trabecular or solid/compact tumor cell proliferation of 
follicular derivation. Such a pattern of growth is shared by several primary tumors of various 
nature, including not only follicular tumors (embryonal adenoma, solid variant of papillary 
carcinoma, Hurthle cell neoplasms, poorly differentiated carcinoma), but also by medullary 
carcinoma and intrathyroid parathyroid tumors. Apart from the differences in cell type and -
obviously- in the ultimate immunoprofile of tumor cells, the trabecular structure is crucial for a 
diagnosis of HTT: thick cords of elongated cells, arranged perpendicular to the major axis of the 
trabecula itself, contain variable amounts of hyaline collagenized material inside the trabeculae, 
to surround individual tumor cells. The general impression is that of a paraganglioma rather than 
a trabecular follicular derived tumor, but the extent of hyalinization may change the overall 
picture and cause misdiagnoses. Indeed, all 15 trabecular cases, including 4 originally submitted 
as HTT, that we deliberately selected among the control cases lacked the PAX8-GLIS3 fusion. 
This supports the notion that the spectrum of trabecular thyroid neoplasms is relatively wide and 
heterogeneous, including a variety of growth patterns in which thick trabeculae merge with 
hyaline material depicting in the end more than one specific follicular derived, benign or 
malignant, entity or subtype. The novel described PAX8-GLIS3 fusion is a valuable hint to take 
HTT apart from its mimickers. 
Interestingly, four HTT cases had associated small papillary carcinomas, which did not 
harbor the GLIS3 fusion product. In addition, in the Nikiforova’s study (10) a link with 
upregulation of genes implicated in collagen type IV deposition was suggested, as the result of 
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the gene rearrangement involving chromosomes 2 and 9, although the exact mechanisms 
remain to be elucidated. The abundance of basal membrane type material included collagen IV 
had been reported in prior immunohistochemical studies by Li and Rosai (38) and Papotti and 
co-workers (12). These molecular and morphological findings may be of further help in taking 
apart real HTT from all the mimickers discussed above, care being taken to identify a 
predominant intratrabecular collagen deposition (rather than in the neoplastic stroma), since such 
a material seems to be the direct result of collagen-related gene upregulation in the fusion-
positive neoplastic cells. 
Finally, as demonstrated by Nikiforova and co-workers using ThyroSeq v3 gene panel in 
over 10,000 FNABs (10, 39), this novel fusion may represent a relevant diagnostic marker of 
HTT in preoperative fine needle aspiration biopsies, especially to take it apart from other 
solid/trabecular thyroid tumors with prominent hyalinization. A correct preoperative 
characterization of HTT can result from molecular methods or from immunohistochemistry for 
GLIS3, to refrain from unnecessary surgery of indeterminate cytology trabecular/follicular 
nodules harboring the PAX8-GLIS3 fusion. 
In conclusion, HTT represents a unique tumor based on its morphological 
(intratrabecular hyalinization, papillary cancer-like nuclei), immunohistochemical (Ki67/MIB1 
expression at the cell membrane) and now also molecular (PAX8-GLIS3 fusion) features. The 
latter support the notion of separately classifying this tumor, as originally proposed by Carney 
(11), taking it apart from both papillary carcinomas and the other conventional follicular thyroid 
neoplasms. 
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FIGURE LEGENDS 
Figure 1: Schematic representation of the tissue samples and sequencing methods 
employed in this study. Depiction of the discovery and of the validation series of hyalinizing 
trabecular tumors (HTTs) of the thyroid, and the comprehensive series of other thyroid 
neoplasms here investigated, including 15 cases (*) in which the morphological features were 
highly reminiscent of an HTT. The sequencing analysis methods utilized in each cohort are 
detailed. 
 
Figure 2: Representative micrographs of hyalinizing trabecular tumors of the thyroid. A 3 
mm large well-circumscribed HTT (A) showing tumor cells arranged in trabeculae and small 
nests with abundant intratrabecular hyaline material (B), and another classical case of HTT (C) 
showing elongated and spindle cells with nuclear palisading and hyaline material in the 
background displaying the unique cell membrane reactivity with the MIB1 monoclonal antibody 
against Ki67 (D). 
 
Figure 3. Representative micrographs of thyroid neoplasms mimicking HTTs. The figure 
illustrates a follicular adenoma of trabecular variant (A, 200x), a poorly differentiated thyroid 
carcinoma (B, 200x), and a Hurthle cell carcinoma (C, 200x) with prominent hyalinization, 
mimicking HTT on morphological ground. No membrane Ki67/MIB1 staining was observed, as 
exemplified here for the case of follicular thyroid adenoma with trabecular features (D, 200x). 
Figure 4: Recurrent PAX8-GLIS3 fusion gene in hyalinizing trabecular tumors of the 
thyroid. A) Schematic representation of the PAX8-GLIS3 fusion transcript including the exons 
and domains involved. The breakpoint of the 5’ and 3’ partner genes are represented as black 
vertical lines. Spanning reads are depicted and aligned to the predicted junction sequence. B) 
Schematic representation showing the Reads Per Kilobase per Million (RPKM) mapped read 
counts of each exon of GLIS3. The GLIS3 fusion breakpoint is represented as a red dashed line. 
C) Representative micrographs of fluorescent in situ hybridization (FISH) for PAX8-GLIS3. D) 
Representative Sanger sequencing electropherograms of the genomic PAX8-GLIS3 breakpoint 
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(Top) and frequency of PAX8-GLIS3 fusion gene in HTTs involved in this study determined by 
RT-PCR (bottom). E) Representative micrograph of fluorescent in situ hybridization (FISH) for 
the absence of PAX8-GLIS3 (top) and frequency of PAX8-GLIS3 fusion gene in HTTs and other 
thyroid neoplasms of the control cohort determined by RT-PCR (bottom). AC: anaplastic 
carcinomas; FA: follicular adenomas; FC: follicular carcinomas; HCT: Hurthle cell tumors; HTT: 
hylinizing trabecular tumors; MC: medullary carcinomas; PDC: poorly differentiated carcinomas; 
PTC: papillary thyroid carcinomas. F) Frequency of PAX8-GLIS3 fusion gene in HTTs analyzed 
in this study and by Nikiforova et al., and other neoplasms as reported by TCGA fusion gene 
database. Hyalinizing trabecular tumor (HTT), Adrenocortical carcinoma (ACC), bladder 
urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell 
carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), colon 
adenocarcinoma (COAD), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), 
esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell 
carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), 
kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), brain lower grade 
glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung 
squamous cell carcinoma (LUSC), mesothelioma (MESO), ovarian serous cystadenocarcinoma 
(OV), pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), 
prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), sarcoma (SARC), skin 
cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), testicular germ cell tumors 
(TGCT), thyroid carcinoma (THCA), thymoma (THYM), uterine corpus endometrial carcinoma 
(UCEC), uterine carcinosarcoma (UCS), uveal melanoma (UVM). 
 
Figure 5. Co-occurrence of a PTC and an HTT in a single patient. The scanned histological 
section contains a small PTC (2 mm, upper right corner of the scanned slide, dashed circle line) 
and a HTT (main lesion, dashed semicircular line). FISH was performed and selected fields were 
scanned within the two lesions, thus demonstrating PAX8-GLIS3 fusions in the HTT (A, B), 
whereas no rearrangements were appreciated in the PTC (C, D). 





